STENTYS a medical technology company today announced its revenue for the third quarter and first 9 months to September 30, 2016.
Over the third quarter of 2016, STENTYS recorded revenues of €1.7 million, up 5% compared with the third quarter of 2015. This growth was more moderate than in previous quarters because of a negative base effect linked to an exceptional order won in the Middle East in 2015, said STENTYS.
Over the first 9 months of 2016, revenues were up 26%, at €5.3 million.